India's pharmaceutical exports to the United Kingdom are projected to exceed $980 million in FY27, representing a significant increase from the $902.96 million worth of pharmaceutical exports recorded between India and the UK in FY26. According to the Pharmaceutical Exports Promotion Council of India (Pharmexcil), this growth is driven by improved access to the British market for Indian drugmakers following the implementation of the Comprehensive Economic and Trade Agreement (CETA). The export promotion body has projected year-on-year growth of nearly 8.66 per cent for the upcoming financial year.
India's pharmaceutical exports to the UK have already demonstrated positive momentum in the early months of FY27. As reported by Pharmexcil, pharmaceutical exports to the UK increased 4.15 per cent year-on-year to $152.14 million during the April-May period of FY27, compared with $146.08 million during the corresponding period last year. This early performance indicates the potential for the projected full-year growth targets to be achieved.
The India-UK free trade agreement is expected to significantly enhance the competitiveness of Indian pharmaceutical exports in the UK market. According to industry experts, the agreement paves the way for zero tariffs on nearly all pharmaceutical products exported from India, making Indian generic medicines more attractive to UK consumers. Pharmexcil Chairman Namit Joshi described the India-UK free trade agreement as a landmark development, noting that the UK is India's largest pharmaceutical export market in Europe and the third-largest globally.
India continues to maintain a strong pharmaceutical trade surplus with the UK, which widened to approximately $767.49 million in FY26. As reported by Pharmexcil, drug formulations and biologicals remained the largest export segment, accounting for 89.54 per cent of India's pharmaceutical exports to the UK. Additionally, exports of active pharmaceutical ingredients (APIs) and bulk drugs reached $72.66 million during the last financial year, highlighting the UK's growing reliance on India's high-quality pharmaceutical manufacturing ecosystem.
The India-UK FTA is expected to deliver multiple benefits beyond trade facilitation. According to Pharmexcil Vice-Chairman Bhavin Mehta, the agreement is anticipated to strengthen supply chains, improve access to affordable medicines, encourage greater foreign direct investment (FDI), and foster deeper collaboration between Indian and UK pharmaceutical companies in manufacturing, research and innovation. With improved regulatory cooperation and a more predictable trade framework, the UK is expected to remain one of the key growth markets for Indian pharmaceuticals, as noted by industry experts.
